selected scholarly activity
-
chapters
- Fusion to Albumin as a Means to Slow the Clearance of Small Therapeutic Proteins Using the Pichia pastoris Expression System. Methods in molecular biology (Clifton, N.J.). 145-154. 2005
-
conferences
- Extending Storage of Thawed Cryoprecipitate from 4 Hours to 24 Hours at 20 degrees C to 24 degrees C Poses a Safety Risk to Transfusion Patients. Transfusion. 76A-77A. 2016
- Identification of alpha-1 proteinase inhibitor variants with enhanced specificity for activated factor XI over thrombin via combined phage display and bacterial lysate screening. Journal of Thrombosis and Haemostasis. 258-258. 2015
- Transfused Plasma Lacking Factor VIII (FVIII) but not Fibrinogen Restores Hemostasis in Coagulopathic Mice. Transfusion. 48A-48A. 2014
- Active site-mutated thrombin S195A but not active site-blocked thrombin counteracts the anticoagulant activity of dabigatran in plasma. Journal of Thrombosis and Haemostasis. 166-166. 2013
- Applying phage display to screen a library of a1-protease inhibitor mutants for thrombin inhibitory activity. Journal of Thrombosis and Haemostasis. 982-983. 2013
- Prothrombin Complex Concentrates Reduce Blood Loss in Mice Rendered Coagulopathic by Warfarin but Not Dabigatran Etexilate. Transfusion. 56A-57A. 2012
- Optimization of modified recombinant albumins that speed clot lysis by competing for crosslinking of antiplasmin. Journal of Thrombosis and Haemostasis. 394-394. 2011
- Retention of thrombin inhibitory activity by recombinant serpins expressed as integral membrane proteins tethered to the surface of mammalian cells. Journal of Thrombosis and Haemostasis. 724-724. 2011
- Equivalent Plasma Quality of Canadian Blood Services' Frozen Plasma Leukoreduced by Centrifugation or Filtration. Transfusion. 60A-60A. 2010
- A Mouse Model to Assess the Efficacy of Plasma Transfusion in the Prevention of Bleeding. Transfusion. 31A-31A. 2009
- Differences Between Frozen Plasmas Produced by the Buffy Coat Method of Whole Blood Processing and Leukoreduced by Centrifugation or Filtration. Transfusion. 80A-81A. 2009
- Development of a mouse model for assessing the efficacy of plasma transfusion in reducing bleeding. Transfusion. 142A-142A. 2008
- Fresh frozen plasma (FFP) sampled from segments differs in coagulation factor assays from FFP sampled from the same bag. Transfusion. 144A-144A. 2008
- Transfused human alpha-1-acid glycoprotein attenuates hepatic inflammation in mice more effectively than human albumin. Transfusion. 147A-147A. 2008
- Two years' national experience of quality monitoring of Canadian frozen plasma products. Transfusion. 147A-147A. 2008
- An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice. Thrombosis and Haemostasis. 1138-1147. 2005
- Either reducing or increasing the molecular volume of recombinant factor IX accelerates its overall clearance in a mouse model of Hemophilia B. Transfusion. 64A-65A. 2004
- Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. British Journal of Haematology. 565-573. 2004
- Accelerated clearance of a recombinant human Factor IX protein lacking activation peptide residues 155-177.. Blood. 91B-91B. 2003
- Use of recombinant forms of Duffy blood group antigen to detect anti-Fy(a) and anti-Fy(b) antibodies. Transfusion. 34A-34A. 2003
- Fusion to albumin alters the clearance of factor IX in vivo. Transfusion. 37S-37S. 2001
- Site-directed mutagenesis at P6 in heparin cofactor II creates a thrombin-inhibitory serpin that is resistant to neutrophil elastase inactivation.. Blood. 46A-47A. 2000
- Production of a recombinant factor IX-albumin fusion protein. Transfusion. 29S-30S. 2000
- Thrombin and neutrophil elastase react with a truncated, his-tagged recombinant heparin cofactor II derivative with seven reactive centre loop residue substitutions at P-6.. Blood. 86B-86B. 1999
- Inhibition of human and rabbit platelet aggregation by recombinant barbourin and barbourin-albumin fusion proteins and derivatives. Thrombosis and Haemostasis. 249-249. 1999
- The reaction of neutrophil elastase with plasma heparin cofactor II and a truncated, his-tagged recombinant derivative.. Thrombosis and Haemostasis. 519-519. 1999
- Genetic fusion of hirudin to albumin prolongs its anticoagulant effects in vivo.. The FASEB Journal. A956-A956. 1998
- Increased in vivo half-life of recombinant hirudin genetically fused to albumin. Thrombosis and Haemostasis. PS361-PS361. 1997
- Mutability of reactive centre loop P4 and P5 residues in human and rabbit antithrombin. Thrombosis and Haemostasis. P1427-P1427. 1997
- Thrombin-antithrombin (TAT) complexes interact with cytokeratin 18 from rabbit hepatocytes. Thrombosis and Haemostasis. P1431-P1431. 1997
- Development of an elastase-resistant antithrombin through mutagenesis at P4.. Blood. 1416-1416. 1995
- Maintenance of tight-binding thrombin inhibition of hirudin fused to albumin via its carboxy-, but not amino-terminus.. Blood. 1419-1419. 1995
- Thrombin-antithrombin (TAT) complexes interact with cytokeratin 18 (CK18) on the surface of hepatocytes.. Blood. 1417-1417. 1995
- A HIRUDIN-ALBUMIN FUSION PROTEIN RETAINS CHARACTERISTICS OF BOTH COMPONENTS. Thrombosis and Haemostasis. 1451-1451. 1995
- CIRCULATORY SURVIVAL OF RECOMBINANT RABBIT ANTITHROMBIN AND DEGLYCOSYLATION MUTANTS. Thrombosis and Haemostasis. 1249-1249. 1995
- DELETION MUTAGENESIS OF HEPARIN COFACTOR-II - DEFINING THE MINIMAL FUNCTIONAL DOMAINS OF A PLASMA THROMBIN INHIBITOR. Thrombosis and Haemostasis. 945-945. 1995
- INTRACELLULAR EVENTS DETERMINE THE FATE OF ANTITHROMBIN UTAH. Thrombosis and Haemostasis. 935-935. 1995
- CHARACTERIZATION OF A HIGHLY POLYMORPHIC TRINUCLEOTIDE SHORT TANDEM REPEAT (STR) WITHIN THE HUMAN ANTITHROMBIN (AT) GENE ON CHROMOSOME-1 - LINKAGE WITH THE AT-HAMILTON ALLELE. Thrombosis and Haemostasis. 751-751. 1993
- CHARACTERIZATION OF A PUTATIVE 45-KDA RABBIT HEPATIC RECEPTOR FOR THROMBIN-ANTITHROMBIN-III (TAT) COMPLEXES. Thrombosis and Haemostasis. 1141-1141. 1993
- SITE-DIRECTED MUTAGENESIS OF HUMAN ANTITHROMBIN RESIDUE-392 (P2) REVEALS A VARIANT WITH ENHANCED BIOLOGICAL-ACTIVITY. Thrombosis and Haemostasis. 1140-1140. 1993
- THE INTERACTION OF THROMBIN-ANTITHROMBIN-III (TAT) COMPLEXES WITH HEPG2 CELLS UP-REGULATES ANTITHROMBIN-III PRODUCTION. Thrombosis and Haemostasis. 760-760. 1993
- USE OF ANTITHROMBIN RECOMBINANT DERIVATIVES AND FUSION PRODUCTS TO MAP ITS HEPARIN-BINDING DOMAINS. Thrombosis and Haemostasis. 1140-1140. 1993
- ANTITHROMBIN-III-STOCKHOLM - A POINT MUTATION IN CODON 392 (GLYCINE TO ASPARTIC-ACID) CAUSING IMPAIRED SERINE PROTEASE REACTIVITY. Thrombosis and Haemostasis. 913-913. 1991
- Molecular Defects in Human Antithrombin III Deficiency. RECOMBINANT TECHNOLOGY IN HEMOSTASIS AND THROMBOSIS. 133-146. 1991
-
journal articles
- Extension of the circulatory half-life of recombinant ecallantide via albumin fusion without loss of anti-kallikrein activity. Journal of Biotechnology. 391:11-19. 2024
- Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized murine model of ITP. Blood Advances. 8:1869-1879. 2024
- Prehospital Freeze-Dried Plasma in Trauma: A Critical Review. Transfusion Medicine Reviews. 38:150807-150807. 2024
- Prolonging the circulatory half-life of C1 esterase inhibitor via albumin fusion.. PLoS ONE. 19:e0305719. 2024
- PB0593 Extending the Circulatory Half-Life of an Engineered Kallikrein-Specific Inhibitor. Research and Practice in Thrombosis and Haemostasis. 7:100785-100785. 2023
- The under‐appreciated world of the serpin family of serine proteinase inhibitors. EMBO Molecular Medicine. 15:e17144. 2023
- Correction of haemorrhagic shock-associated coagulopathy and impaired haemostasis by plasma, prothrombin complex concentrates or an activated protein C-targeted DNA aptamer in mice. Scientific Reports. 13:3811. 2023
- A positive blood culture is associated with a lower haemoglobin increment in hospitalized patients after red blood cell transfusion. Vox Sanguinis. 118:33-40. 2023
- Minimal impact of anticoagulant on in vitro whole blood quality throughout a 35‐day cold‐storage regardless of leukoreduction timing. Transfusion. 62:S98-S104. 2022
- Spotlight on animal models of acute traumatic coagulopathy: an update. Transfusion and Apheresis Science. 61:103412-103412. 2022
- Challenging the 30‐min rule for thawed plasma. Vox Sanguinis. 117:328-336. 2022
- Rejuvenated and safe: Freeze‐dried plasma for the 21st century. Transfusion. 62:257-260. 2022
-
Retention of hemostatic and immunological properties of frozen plasma and
COVID ‐19 convalescent apheresis fresh‐frozen plasma produced and freeze‐dried in Canada. Transfusion. 62:418-428. 2022 - Inductively-Coupled Plasma Mass Spectrometry–Novel Insights From an Old Technology Into Stressed Red Blood Cell Physiology. Frontiers in Physiology. 13:828087. 2022
- The bending rigidity of the red blood cell cytoplasmic membrane. PLoS ONE. 17:e0269619-e0269619. 2022
- Cold‐stored leukoreduced whole blood: Extending the time between donation and filtration has minimal impact on in vitro quality. Transfusion. 61:S131-S143. 2021
- Pathogen reduction of whole blood: Supplementing fibrinogen partly corrects clot formation in a massive transfusion model. Transfusion. 61:1884-1893. 2021
- Identification of an alpha-1 antitrypsin variant with enhanced specificity for factor XIa by phage display, bacterial expression, and combinatorial mutagenesis. Scientific Reports. 11:5565. 2021
- Selection and in vitro and in vivo characterization of a Kunitz protease inhibitor domain of protease nexin 2 variant that inhibits factor XIa without inhibiting plasmin. Journal of Biotechnology. 330:61-69. 2021
- Blood bank storage of red blood cells increases RBC cytoplasmic membrane order and bending rigidity. PLoS ONE. 16:e0259267-e0259267. 2021
- Cold-stored leukoreduced whole blood: no impact of extended time between donation and filtration on in vitro quality. Transfusion Medicine Reviews. 35:56-56. 2021
- Stepwise Reversion of Multiply Mutated Recombinant Antitrypsin Reveals a Selective Inhibitor of Coagulation Factor XIa as Active as the M358R Variant. Frontiers in Cardiovascular Medicine. 8:647405. 2021
- Thrombospondin-1/CD47 signaling modulates transmembrane cation conductance, survival, and deformability of human red blood cells. Cell Communication and Signaling. 18:155. 2020
- Stabilization of Lipid Membranes through Partitioning of the Blood Bag Plasticizer Di-2-ethylhexyl phthalate (DEHP). Langmuir. 36:11899-11907. 2020
- Engineering the serpin α1‐antitrypsin: A diversity of goals and techniques. Protein Science. 29:856-871. 2020
- Corrigendum to “Comparison of mammalian and bacterial expression library screening to detect recombinant alpha-1 proteinase inhibitor variants with enhanced thrombin inhibitory capacity” [J. Biotechnol. 208 (2015) 54–62]. Journal of Biotechnology. 311:59-59. 2020
- Decoding the metabolic landscape of pathophysiological stress-induced cell death in anucleate red blood cells.. Blood Transfusion. 18:130-142. 2020
- Correction: Phage Display of the Serpin Alpha-1 Proteinase Inhibitor Randomized at Consecutive Residues in the Reactive Centre Loop and Biopanned with or without Thrombin. PLoS ONE. 15:e0238969-e0238969. 2020
- Prothrombin, alone or in complex concentrates or plasma, reduces bleeding in a mouse model of blood exchange-induced coagulopathy. Scientific Reports. 9:13029. 2019
- A factor XIa-activatable hirudin-albumin fusion protein reduces thrombosis in mice without promoting blood loss. BMC Biotechnology. 18:21. 2018
- Extending the pre-processing holding time of whole blood beyond 48 h reduces coagulation FVIII activity and immunoglobulin G content of recovered plasma. Transfusion and Apheresis Science. 57:768-772. 2018
- Thromboelastometry reveals similar hemostatic properties of purified fibrinogen and a mixture of purified cryoprecipitate protein components. Clinical Chemistry and Laboratory Medicine. 56:e210-e213. 2018
- Bacterial neuraminidase‐mediated erythrocyte desialylation provokes cell surface aminophospholipid exposure. European Journal of Haematology. 100:502-510. 2018
- Red blood cells, still vital after all these years: Commentary on Canadian Blood Services’ International Symposium 2017. Transfusion and Apheresis Science. 57:298-303. 2018
- Fusion to Human Serum Albumin Extends the Circulatory Half-Life and Duration of Antithrombotic Action of the Kunitz Protease Inhibitor Domain of Protease Nexin 2. Cellular Physiology and Biochemistry. 45:772-782. 2018
- Serpin Phage Display: The Use of a T7 System to Probe Reactive Center Loop Libraries with Different Serine Proteinases. Methods in molecular biology (Clifton, N.J.). 1826:41-64. 2018
- Bacteria can proliferate in thawed cryoprecipitate stored at room temperature for longer than 4 h. Vox Sanguinis. 112:477-479. 2017
- Comparison of bacterial attachment to platelet bags with and without preconditioning with plasma. Vox Sanguinis. 112:401-407. 2017
-
Early γ‐irradiation and subsequent storage of red cells in
SAG ‐M additive solution potentiate energy imbalance, microvesiculation and susceptibility to stress‐induced apoptotic cell death. Vox Sanguinis. 112:480-483. 2017 - Intersecting Worlds of Transfusion and Transplantation Medicine: An International Symposium Organized by the Canadian Blood Services Centre for Innovation. Transfusion Medicine Reviews. 31:183-192. 2017
- Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa. Scientific Reports. 7:2102. 2017
- Pathogen inactivation by riboflavin and ultraviolet light illumination accelerates the red blood cell storage lesion and promotes eryptosis. Transfusion. 57:661-673. 2017
- Quality and Safety of Blood Products. Journal of Blood Transfusion. 2016:1-2. 2016
- Quality Assessment of Established and Emerging Blood Components for Transfusion. Journal of Blood Transfusion. 2016:1-28. 2016
- Stability of Thawed Apheresis Fresh-Frozen Plasma Stored for up to 120 Hours at 1°C to 6°C. Journal of Blood Transfusion. 2016:1-7. 2016
- Thrombolysis by chemically modified coagulation factor Xa. Journal of Thrombosis and Haemostasis. 14:1844-1854. 2016
- Selection and Characterization of a DNA Aptamer Inhibiting Coagulation Factor XIa. Transfusion Medicine Reviews. 30:146-147. 2016
- CD44 Antibody Inhibition of Macrophage Phagocytosis Targets Fcγ Receptor– and Complement Receptor 3–Dependent Mechanisms. Journal of Immunology. 196:3331-3340. 2016
- Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium. Transfusion Medicine Reviews. 30:53-68. 2016
- Phosphatidylserine externalization and procoagulant activation of erythrocytes induced by Pseudomonas aeruginosa virulence factor pyocyanin. Journal of Cellular and Molecular Medicine. 20:710-720. 2016
- The M358R variant of α 1 -proteinase inhibitor inhibits coagulation factor VIIa. Biochemical and Biophysical Research Communications. 470:710-713. 2016
- Monovalent Fc receptor blockade by an anti–Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity. Blood. 127:132-138. 2016
- Stability of coagulation protein activities in single units or pools of cryoprecipitate during storage at 20–24°C for up to 24 h. Vox Sanguinis. 110:12-19. 2016
- Accelerated apoptotic death and in vivo turnover of erythrocytes in mice lacking functional mitogen- and stress-activated kinase MSK1/2. Scientific Reports. 5:17316. 2015
- Comparison of mammalian and bacterial expression library screening to detect recombinant alpha-1 proteinase inhibitor variants with enhanced thrombin inhibitory capacity☆. Journal of Biotechnology. 208:54-62. 2015
- Fluorous Analogue of Chloramine-T: Preparation, X-ray Structure Determination, and Use as an Oxidant for Radioiodination and s-Tetrazine Synthesis. Journal of Organic Chemistry. 80:7117-7125. 2015
- Plasma and Plasma Protein Product Transfusion: A Canadian Blood Services Centre for Innovation Symposium. Transfusion Medicine Reviews. 29:181-194. 2015
- A plasmin-activatable thrombin inhibitor reduces experimental thrombosis and assists experimental thrombolysis in murine models. Journal of Thrombosis and Thrombolysis. 39:443-451. 2015
-
The fibrinogen but not the
F actorVIII content of transfused plasma determines its effectiveness at reducing bleeding in coagulopathic mice. Transfusion. 55:1040-1050. 2015 - Whole blood treated with riboflavin and ultraviolet light: quality assessment of all blood components produced by the buffy coat method. Transfusion. 55:815-823. 2015
- Alpha-1 proteinase inhibitor M358R reduces thrombin generation when displayed on the surface of cells expressing tissue factor. Thrombosis Research. 134:1142-1149. 2014
- γT‐S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo. Journal of Thrombosis and Haemostasis. 12:1110-1115. 2014
- Platelet Utilization: A Canadian Blood Services Research and Development Symposium. Transfusion Medicine Reviews. 28:84-97. 2014
- Stability of relevant plasma protein activities in cryosupernatant plasma units during refrigerated storage for up to 5 days postthaw. Transfusion. 54:418-425. 2014
- Alpha‐1 Acid Glycoprotein Reduces Hepatic Leukocyte Recruitment in Murine Models of Either Early Endotoxemia or Early Sepsis. Microcirculation. 21:74-83. 2014
- Phage Display of the Serpin Alpha-1 Proteinase Inhibitor Randomized at Consecutive Residues in the Reactive Centre Loop and Biopanned with or without Thrombin. PLoS ONE. 9:e84491-e84491. 2014
- Expression screening of bacterial libraries of recombinant alpha-1 proteinase inhibitor variants for candidates with thrombin inhibitory capacity. Journal of Biotechnology. 168:373-381. 2013
- Fusion of the C-terminal triskaidecapeptide of hirudin variant 3 to alpha1-proteinase inhibitor M358R increases the serpin-mediated rate of thrombin inhibition. BMC Biochemistry. 14:31. 2013
- Quality of frozen transfusable plasma prepared from whole blood donations in Canada: An update. Transfusion and Apheresis Science. 49:440-446. 2013
- The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand. BMC Biochemistry. 14:6. 2013
- Covalent Stabilization Of Coagulation Factor Xa Enhances Its Fibrinolytic Function In Vitro and In Vivo: A Novel Cofactor-Based Thrombolytic Agent. Blood. 122:204-204. 2013
- Process Improvement by Eliminating Mixing of Whole Blood Units after an Overnight Hold Prior to Component Production Using the Buffy Coat Method. Journal of Blood Transfusion. 2013:1-7. 2013
- Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. Journal of Thrombosis and Haemostasis. 10:1830-1840. 2012
- Characterization of a long-acting recombinant human serum albumin-atrial natriuretic factor (ANF) expressed in Pichia pastoris. Peptides. 175:7-10. 2012
- Changes in coagulation factor activity and content of di(2‐ethylhexyl)phthalate in frozen plasma units during refrigerated storage for up to five days after thawing. Transfusion. 52:493-502. 2012
- In VivoClearance of Alpha-1 Acid Glycoprotein Is Influenced by the Extent of Its N-Linked Glycosylation and by Its Interaction with the Vessel Wall. BioMed Research International. 2012:1-11. 2012
- Reduction of thrombus size in murine models of thrombosis following administration of recombinant α1-proteinase inhibitor mutant proteins. Thrombosis and Haemostasis. 107:972-984. 2012
- Incorporation of albumin fusion proteins into fibrin clots in vitro and in vivo: comparison of different fusion motifs recognized by factor XIIIa. BMC Biotechnology. 11:127. 2011
- Retention of thrombin inhibitory activity by recombinant serpins expressed as integral membrane proteins tethered to the surface of mammalian cells. Journal of Thrombosis and Haemostasis. 9:2424-2435. 2011
- Lipoprotein enrichment in orange insoluble particulate matter reproducibly appearing in cryoprecipitate. Vox Sanguinis. 100:422-425. 2011
- Comparison of Methods for the Purification of Alpha‐1 Acid Glycoprotein from Human Plasma. BioMed Research International. 2011:578207. 2011
- Conversion to the buffy coat method and quality of frozen plasma derived from whole blood donations in Canada. Transfusion. 50:1043-1049. 2010
- Sporadic formation of cryoprecipitate‐like particulate matter in thawed fresh‐frozen plasma units. Transfusion. 50:949-950. 2010
- A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo. Thrombosis and Haemostasis. 101:867-877. 2009
- Addition of a sequence from α2-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis. BMC Biotechnology. 9:15-15. 2009
- Factor VIIa gets even bigger. Thrombosis and Haemostasis. 99:653-654. 2008
- EXTRA- AND INTRA-REACTIVE CENTRE LOOP ALTERATIONS TO ALPHA-1-PROTEINASE INHIBITOR ENHANCE ITS SPECIFIC INHIBITION OF THROMBIN. Journal of Thrombosis and Haemostasis. 5:o-t-087-o-t-087. 2007
- Combined administration of barbourin–albumin and hirudin–albumin fusion proteins limits fibrin(ogen) deposition on the rabbit balloon-injured aorta. Thrombosis Research. 119:195-207. 2007
- The appended tail region of heparin cofactor II and additional reactive centre loop mutations combine to increase the reactivity and specificity of α1-proteinase inhibitor M358R for thrombin. Thrombosis and Haemostasis. 98:1014-1023. 2007
- Detection of antibodies reacting with the antithetical duffy blood group antigens Fya and Fyb using recombinant fusion proteins containing the duffy extracellular domain. Transfusion and Apheresis Science. 35:207-216. 2006
- The Transferable Tail: Fusion of the N-Terminal Acidic Extension of Heparin Cofactor II to α1-Proteinase Inhibitor M358R Specifically Increases the Rate of Thrombin Inhibition. Biochemistry. 45:11444-11452. 2006
- Molecular cloning and functional expression of rabbit α2-antiplasmin. Blood Coagulation and Fibrinolysis. 17:283-291. 2006
- Investigating serpin–enzyme complex formation and stability via single and multiple residue reactive centre loop substitutions in heparin cofactor II. Thrombosis Research. 117:447-461. 2006
- Blood Group Biochemistry: A Canadian Blood Services Research and Development Symposium. Transfusion Medicine Reviews. 19:295-307. 2005
- Alpha-1-acid glycoprotein reduces hepatic leukocyte recruitment in early sepsis. Critical Care. 9:P189-P189. 2005
- Fusion to Albumin as a Means to Slow the Clearance of Small Therapeutic Proteins Using the <I>Pichia pastoris</I> Expression System: A Case Study. Methods in molecular biology (Clifton, N.J.). 308:145-154. 2005
- Recombinant albumins containing additional peptide sequences smaller than barbourin retain the ability of barbourin-albumin to inhibit platelet aggregation. Thrombosis and Haemostasis. 93:914-921. 2005
- Full or Partial Substitution of the Reactive Center Loop of α-1-Proteinase Inhibitor by that of Heparin Cofactor II: P1 Arg Is Required for Maximal Thrombin Inhibition. Biochemistry. 43:14864-14872. 2004
- A covalently linked recombinant albumin dimer is more rapidly cleared in vivo than are wild-type and mutant C34A albumin. Translational Research. 143:115-124. 2004
- Heparin cofactor II is more sensitive than antithrombin to secretory impairment arising from mutations introduced into its carboxy-terminal region. Thrombosis Research. 113:163-173. 2004
- Altering Heparin Cofactor II at VAL439 (P6) either Impairs Inhibition of Thrombin or Confers Elastase Resistance. Thrombosis and Haemostasis. 88:89-97. 2002
- Prolonged in vivo anticoagulant activity of a hirudin–albumin fusion protein secreted from Pichia pastoris. Blood Coagulation and Fibrinolysis. 12:433-443. 2001
- Modification of Clearance of Therapeutic and Potentially Therapeutic Proteins. Cardiovascular and Hematological Disorders - Drug Targets. 1:1-22. 2001
- A Barbourin-albumin Fusion Protein that Is Slowly Cleared In Vivo Retains the Ability to Inhibit Platelet Aggregation In Vitro. Thrombosis and Haemostasis. 86:902-908. 2001
- Site-directed mutagenesis at p6 in heparin cofactorii creates a thrombin-inhibitory serpin that is resistant to neutrophil elastaseinac1tvation. Blood. 96. 2000
- Modulation of Clearance of Recombinant Serum Albumin by Either Glycosylation or Truncation. Thrombosis Research. 99:613-621. 2000
- Mutation of Any Site of N-Linked Glycosylation Accelerates the In Vivo Clearance of Recombinant Rabbit Antithrombin. Thrombosis Research. 99:407-415. 2000
- The Clearance of Thrombin-antithrombin and Related Serpin-enzyme Complexes from the Circulation: Role of Various Hepatocyte Receptors. Thrombosis and Haemostasis. 81:325-337. 1999
- Cytokeratin 18 Is Expressed on the Hepatocyte Plasma Membrane Surface and Interacts with Thrombin-Antithrombin Complexes. Journal of Biological Chemistry. 272:28574-28581. 1997
- IMPACT OF MUTATIONS AT THE P4 AND P5 POSITIONS ON THE REACTION OF ANTITHROMBIN WITH THROMBIN AND ELASTASE. Thrombosis Research. 88:171-181. 1997
- Concepts and techniques in molecular biology—An overview*. Transfusion Medicine Reviews. 11:209-223. 1997
- Potent Antithrombin Activity and Delayed Clearance From the Circulation Characterize Recombinant Hirudin Genetically Fused to Albumin. Blood. 89:3243-3252. 1997
- INHIBITION OF THROMBIN BY HIRUDIN GENETICALLY FUSED TO WILD-TYPE OR MUTANT ANTITHROMBIN. Thrombosis Research. 84:419-429. 1996
- Intracellular events determine the fate of antithrombin Utah. Blood. 86:3461-3467. 1995
- Deletion mutagenesis of heparin cofactor II: defining the minimum size of a thrombin inhibiting serpin. FEBS Letters. 365:189-192. 1995
- Amino acid substitutions of the P2 residue of human antithrombin that either enhance or impair function. Thrombosis Research. 75:293-305. 1994
- Genetic linkage studies in antithrombin‐deficient kindreds using a highly polymorphic trinucleotide short tandem repeat (str) within the human antithrombin gene. American Journal of Hematology. 46:107-111. 1994
- Characterization of a highly polymorphic trinucleotide short tandem repeat within the human antithrombin gene. Thrombosis Research. 74:303-307. 1994
- Site‐directed mutagenesis of the P2 residue of human antithrombin. FEBS Letters. 339:147-150. 1994
- Defining the heparin-binding domain of antithrombin. Blood Coagulation and Fibrinolysis. 5:83-96. 1994
- Molecular Cloning and Expression of Rabbit Heparin Cofactor II: A Plasma Thrombin Inhibitor Highly Conserved between Species. Thrombosis and Haemostasis. 71:778-782. 1994
- Complete nucleotide sequence of the cdna encoding rabbit coagulation factor VII. Thrombosis Research. 69:231-238. 1993
- Molecular basis of inherited human antithrombin deficiency. Blood. 80:2159-2171. 1992
- Molecular basis of inherited human antithrombin deficiency. Blood. 80:2159-2171. 1992
- Molecular cloning and expression of rabbit antithrombin III. Blood. 79:2330-2339. 1992
- Antithrombin-III-Stockholm: a codon 392 (Gly----Asp) mutation with normal heparin binding and impaired serine protease reactivity. Blood. 79:1428-1434. 1992
- Antithrombin-III-Stockholm: a codon 392 (Gly----Asp) mutation with normal heparin binding and impaired serine protease reactivity. Blood. 79:1428-1434. 1992
- The N-terminal domain of antithrombin-III is essential for heparin binding and complex-formation with, but not cleavage by, α-thrombin. Biochemical Journal. 282:345-351. 1992
- Molecular Cloning and Cell-Free Expression of Mouse Antithrombin III. Thrombosis and Haemostasis. 68:291-296. 1992
- Mitochondrial precursor protein. Effects of 70-kilodalton heat shock protein on polypeptide folding, aggregation, and import competence.. Journal of Biological Chemistry. 265:11069-11076. 1990
- Import of precursor proteins into mitochondria: site of polypeptide unfolding.. Journal of Biological Chemistry. 265:9444-9451. 1990
- Regulation of Ornithine Aminotransferase in Retinoblastomas. Journal of Biological Chemistry. 264:20513-20517. 1989
- Identification of hydrophobic residues in the signal sequence of mitochondrial preornithine carbamyltransferase that enhance the rate of precursor import.. Journal of Biological Chemistry. 263:17233-17236. 1988
- A signal sequence domain essential for processing, but not import, of mitochondrial pre-ornithine carbamyl transferase.. Journal of Cell Biology. 104:1193-1198. 1987
- Expression in Escherichiacoli of functional precursor to the rat liver mitochondrial enzyme, ornithine carbamyl transferase. Precursor import and processing in vitro. Biochemical and Biophysical Research Communications. 134:21-28. 1986